Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
21.35 HKD | +0.95% | +3.37% | -8.70% |
04-29 | CanSino Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-22 | Cansino Bio Gets Nod for China Clinical Trials of Haemophilus Influenzae Vaccine | MT |
ETFs positioned on CanSino Biologics Inc.
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.75% | 4 M€ | -27.92% | ||
0.11% | 3 M€ | +7.43% | - | |
0.01% | 35 M€ | -5.85% | - | |
0.01% | 112 M€ | +5.68% | - | |
0.00% | 32 M€ | +8.96% | - | |
0.00% | 34 M€ | +8.23% | - | |
0.00% | 7 M€ | +6.66% | - | |
0.00% | 391 M€ | +9.18% | - | |
0.00% | 39 M€ | +5.99% | - | |
0.00% | 306 M€ | +6.45% | - | |
0.00% | 34 M€ | +4.06% | - | |
0.00% | 17 M€ | +2.74% | - | |
0.00% | 105 M€ | +4.05% | - | |
0.00% | 54 M€ | +1.07% | - | |
0.00% | 8 M€ | +0.48% | - |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.70% | 1.18B | |
-0.07% | 91.42B | |
+2.76% | 41.08B | |
-9.06% | 34.26B | |
+55.32% | 25.27B | |
-16.61% | 15.27B | |
-9.14% | 12.81B | |
-12.11% | 11.6B | |
-43.61% | 11.42B | |
+7.79% | 9.16B |
- Stock Market
- Equities
- 6185 Stock
- Funds and ETFs CanSino Biologics Inc.